Healthcare providers can offer insights into the latest research, weigh the evidence, and provide recommendations based on their expertise
Semaglutides clinical efficacy profile , characterised by HbA1c reductions of 1.52.0% and body weight reductions of 1015% with subcutaneous dosing and up to 17% with the higher-dose Wegovy formulation , represents the highest efficacy achieved by any selective GLP-1R agonist and substantially exceeds the outcomes achieved with liraglutide, exenatide, and earlier GLP-1R agonists
The Si OBP15 protein interacts with the proteins encoded by Si ApoLp-III and Si FABP5 genes, which are involved in the insects innate immunity and help to regulate dismemberment behavior (Zhang et al., 2025)
Real-world safety beyond two years remains largely unstudied in semaglutide's weight-loss indication
Initial weight loss may be gradual as the body adapts to the medication
Considerations for Use While semaglutide presents many benefits, it is essential to consult with a healthcare provider before initiating treatment